Galectin-Ig Fusion Constructs Oxidative Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant Galectin-1 proteins require reducing agents to maintain stability and function, limiting their therapeutic applications due to oxidative inactivation and instability, especially in human anti-inflammatory and apoptotic studies.
Innovation Solution
Development of Galectin-Ig fusion constructs that combine a Galectin-1 polypeptide with an Fc fragment of an immunoglobulin, linked in frame with a linker sequence, which maintains stability and pro-apoptotic activity without the need for reducing agents, allowing for effective use in therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If reducing agents are used to maintain Galectin-1 stability, then protein stability is improved, but therapeutic applicability deteriorates due to safety concerns and operational complexity
Solution Approach 1:
The invention extracts and removes the requirement for reducing agents from the Galectin-1 system by engineering a mutant Galectin-1 variant that inherently resists oxidative inactivation, thereby eliminating the need for external stabilizing agents while maintaining protein stability
Solution Approach 2:
The invention changes the amino acid sequence parameters of Galectin-1 through site-directed mutagenesis, specifically modifying cysteine residues to reduce susceptibility to oxidation, thereby altering the protein's chemical properties to achieve stability without reducing agents
2Reliability
If wild-type Galectin-1 is used, then natural ligand binding activity is preserved, but oxidative inactivation occurs leading to loss of function
Solution Approach 1:
The invention applies local quality modification by specifically targeting and mutating only the cysteine residues involved in disulfide bond formation and oxidation susceptibility, while leaving the rest of the Galectin-1 structure intact to preserve ligand binding activity
Solution Approach 2:
The invention converts the harmful effect of oxidation by designing mutant Galectin-1 variants that are resistant to oxidative damage, thereby transforming the vulnerability of wild-type Galectin-1 to oxidation into a beneficial property of enhanced stability and prolonged function
Data Source
AI summary
Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.